# FORM 4

Theck this box if no longer subject to ection 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses)   |                             |                       |   |                                 |       |  |                 |         |   |  |            |
|---|-----------------------------|-----------------------|---|---------------------------------|-------|--|-----------------|---------|---|--|------------|
| 1. Name and Address of Reporting Person –<br>WEINER BARRY W           |                             |                       | Name <b>and</b> Ticker or<br>BIOCHEM INC [H | 0,                              |       |  |                 | :       | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>_X_Director10% Owner  |  |            |
| (Last) (First) (Middle)<br>C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE |                             | 3. Date of 02/24/20   | Earliest Transaction (<br>020               | Month/Day/Year)                 |       |  |                 |         | _X_ Officer (give title below)Other (specify below) PRESIDENT AND TREASURER   |  |            |
| (Street)<br>NEW YORK, NY 10022  |                             | 4. If Ame<br>02/26/20 | ndment, Date Original<br>020                | Filed(Month/Day/Yes             | ir)   |  |                 |         | 6. Individual or Joint/Group Filing(Check Applicable Line)<br>X. Form filed by One Reporting Person<br>Form filed by More than One Reporting Person |  |            |
| (City) (State) (Zip)  |                             |                       |   |                                 | Table | I - Non-Deriv  | ative Securitie | s Acqui | red, Disposed of, or Beneficially Owned   |  |            |
| 1.Title of Security<br>(Instr. 3)                                     | 2. Transactie<br>(Month/Day | //Year)               | 2A. Deemed<br>Execution Date, if<br>any     | 3. Transaction Co<br>(Instr. 8) | de    | <ol> <li>Securities<br/>Disposed of<br/>(Instr. 3, 4 ar</li> </ol> |                 | er      | 5. Amount of Securities Beneficially Owned Following Reported<br>Transaction(s)<br>(Instr. 3 and 4)   |  | Beneficial |
|   |                             |                       | (Month/Day/Year)                            | Code                            | v     | Amount   | (A) or (D)      | Price   |   | Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) |            |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

|   |        |                  |                                | (e.g., | puts, cans, warrants, op  | otions, co | nvertible securitie  | es)                |   |                               |                                      |   |   |                         |
|---|--------|------------------|--------------------------------|--------|---|------------|--|--------------------|---|-------------------------------|--------------------------------------|---|---|-------------------------|
|   |        | (Month/Day/Year) | 4. Transaction (<br>(Instr. 8) |        | 5. Number of Derivativ<br>Securities Acquired (A<br>Disposed of (D)<br>(Instr. 3, 4, and 5) | ) or       | <ol> <li>Date Exercisation Date</li> <li>(Month/Day/Year)</li> </ol> |                    | 7. Title and Amou<br>Securities<br>(Instr. 3 and 4) | , , , ,                       | Derivative<br>Security<br>(Instr. 5) | Securities<br>Beneficially              | Ownership<br>Form of<br>Derivative                          | Beneficial<br>Ownership |
|   |        |                  | Code                           | v      | (A)   | (D)        | Date<br>Exercisable  | Expiration<br>Date |   | Amount or Number of<br>Shares |                                      | Following<br>Reported<br>Transaction(s) | Security:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) |                         |
| Stock Option (to acquire<br>Common Stock) | \$ 2.2 | 02/24/2020       | А                              |        | 116,900   |            | 02/24/2021(1)  | 02/24/2025         | Common<br>Stock                                     | 116,900                       | \$ 0                                 | 268,389 (2)                             | D   |                         |

### **Reporting Owners**

|  | Relationships |              |                         |       |  |  |  |  |
|--|---------------|--------------|-------------------------|-------|--|--|--|--|
| Reporting Owner Name / Address   | Director      | 10%<br>Owner | Officer                 | Other |  |  |  |  |
| WEINER BARRY W<br>C/O ENZO BIOCHEM, INC.<br>527 MADISON AVENUE<br>NEW YORK, NY 10022 | х             |              | PRESIDENT AND TREASURER |       |  |  |  |  |

# Signatures

| /s/ Barry W. Weiner             | 02/27/2020 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date       |

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Reporting Person was granted 116,900 stock options. The stock options have a five-year term and will vest in two equal installments, one on the first anniversary of the grant date and the other on the second anniversary of the grant date.

(2) Does not include 25,300 Performance Stock Units granted to the Reporting Person on February 24, 2020, which will vest, if at all, based on (i) the achievement of certain average revenue growth and average adjusted EBITDA growth goals on February 24, 2023 and (ii) the continued em through February 24, 2023.

#### Remarks:

This amendment is being filed to correct the original Form 4, filed on February 26, 2020, which misreported (i) the expiration date/term of the stock options granted to the Reporting Person and (ii) the number of Performance Stock Units

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.